Haemonetics (NYSE:HAE) will be releasing its earnings data before the market opens on Tuesday, February 6th. Analysts expect Haemonetics to post earnings of $0.44 per share for the quarter. Haemonetics has set its FY18 guidance at $1.65-1.75 EPS.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.07. The firm had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.38 EPS. On average, analysts expect Haemonetics to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Shares of Haemonetics (NYSE:HAE) opened at $63.45 on Monday. Haemonetics has a 1 year low of $36.44 and a 1 year high of $67.27. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51. The stock has a market capitalization of $3,351.30, a PE ratio of 793.22, a P/E/G ratio of 4.79 and a beta of 1.06.

A number of analysts have weighed in on HAE shares. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a research report on Wednesday, October 25th. Morgan Stanley raised Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a research report on Tuesday, January 2nd. Raymond James Financial raised Haemonetics from an “underperform” rating to a “market perform” rating in a research report on Tuesday, January 2nd. Jefferies Group increased their price objective on Haemonetics from $18.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, January 8th. Finally, Craig Hallum reaffirmed a “hold” rating and set a $50.00 price objective (up from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $58.83.

In other Haemonetics news, Director Susan Bartlett Foote sold 16,926 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $54.19, for a total transaction of $917,219.94. Following the completion of the sale, the director now directly owns 27,313 shares of the company’s stock, valued at approximately $1,480,091.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronald G. Gelbman sold 5,440 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $56.69, for a total value of $308,393.60. The disclosure for this sale can be found here. Insiders have sold a total of 54,486 shares of company stock valued at $3,050,827 over the last ninety days. 1.20% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Haemonetics (HAE) to Release Earnings on Tuesday” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/haemonetics-hae-to-release-earnings-on-tuesday/1844803.html.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Earnings History for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.